Divi's Laboratories 配当と自社株買い
配当金 基準チェック /46
Divi's Laboratoriesは配当を支払う会社で、現在の利回りは0.36%ですが、利益によって十分にカバーされています。次の支払い日は 9th September, 2026で、権利落ち日は24th July, 2026 。
主要情報
0.4%
配当利回り
n/a
バイバック利回り
| 総株主利回り | n/a |
| 将来の配当利回り | 0.6% |
| 配当成長 | 13.5% |
| 次回配当支払日 | 09 Sep 26 |
| 配当落ち日 | 24 Jul 26 |
| 一株当たり配当金 | n/a |
| 配当性向 | 31% |
最近の配当と自社株買いの更新
Recent updates
分析記事 • 10h
Divi's Laboratories Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
A week ago, Divi's Laboratories Limited ( NSE:DIVISLAB ) came out with a strong set of quarterly numbers that could...
ナラティブ更新 • Jul 23
DIVISLAB: Elevated Future P/E Will Continue To Signal Overvaluation Risk
Analysts have revised their price target for Divi's Laboratories to ₹5,610 from ₹5,333.98, citing updated assumptions for revenue growth, profit margins, and future P/E that collectively support a higher fair value estimate despite a slightly higher discount rate. What’s in the News for Divi's Laboratories A board meeting is scheduled on August 1, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.
ナラティブ更新 • Jul 08
DIVISLAB: Upcoming Board Decisions And Fair Value Assumptions Will Shape Balanced Outlook
Analysts have modestly raised their price target for Divi's Laboratories from ₹6,875 to approximately ₹7,059, citing updated assumptions around fair value, discount rate, revenue growth, profit margins and future P/E expectations. What's in the News Divi's Laboratories has scheduled a board meeting on May 23, 2026, at 10:15 Indian Standard Time to review audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
ナラティブ更新 • Jun 24
DIVISLAB: Upcoming Board Meeting And Dividend Decision Will Support Bullish Outlook
Analysts have adjusted their fair value estimate for Divi's Laboratories slightly lower from ₹8,812.63 to ₹8,795.18, reflecting small tweaks to assumptions on the discount rate, revenue growth, profit margin and future P/E multiples. What’s in the News for Divi's Laboratories A board meeting is scheduled for May 23, 2026, at 10:15 Indian Standard Time to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.ナラティブ更新 • Jun 09
DIVISLAB: Upcoming Board Meeting And Dividend Decision Will Support Bullish Outlook
Analysts have raised their fair value estimate for Divi's Laboratories from ₹8,620.23 to ₹8,812.63, reflecting updated assumptions for the discount rate, revenue growth, profit margins and future P/E expectations. What's in the News A board meeting is scheduled for May 23, 2026, at 10:15 IST to review and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.ナラティブ更新 • May 26
DIVISLAB: Elevated Future P/E Will Continue To Signal Overvaluation Risk
Analysts have lifted Divi's Laboratories price target from ₹5,133.17 to ₹5,333.98, citing updated assumptions on revenue growth, profit margins, and future P/E expectations. What's in the News A board meeting is scheduled for May 23, 2026, at 10:15 Indian Standard Time to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026 (Key Developments).分析記事 • May 26
Divi's Laboratories Limited (NSE:DIVISLAB) Just Released Its Annual Results And Analysts Are Updating Their Estimates
Divi's Laboratories Limited ( NSE:DIVISLAB ) last week reported its latest yearly results, which makes it a good time...ナラティブ更新 • May 04
DIVISLAB: Elevated Future P/E Will Remain A Key Overvaluation Risk
Analysts have trimmed their price target on Divi's Laboratories slightly from ₹5,140 to about ₹5,133, reflecting updated assumptions around discount rates, revenue growth, profit margin, and future P/E expectations. Valuation Changes Fair Value: Trimmed slightly from ₹5,140.00 to about ₹5,133.17 per share.ナラティブ更新 • Apr 20
DIVISLAB: Upcoming Board Review Will Support Bullish Long Term Outlook
Analysts have lifted their price target for Divi's Laboratories slightly, with fair value now seen around ₹8,620 versus about ₹8,554 earlier, reflecting updated assumptions for discount rate, revenue growth, profit margin and future P/E. What's in the News A board meeting is scheduled on Feb 11, 2026 to consider and approve unaudited standalone financial results for the quarter and nine months ended Dec 31, 2025 (Key Developments).ナラティブ更新 • Apr 05
DIVISLAB: Elevated Future P/E Will Persist Despite Unchanged Fair Value Estimate
Analysts have maintained Divi's Laboratories' fair value estimate at ₹5,140 per share, with only small tweaks to assumptions such as discount rate, revenue growth, profit margin, and future P/E, which together guide the latest price target narrative. What's in the News Board meeting scheduled for February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (Key Developments).ナラティブ更新 • Mar 22
DIVISLAB: Upcoming Board Review And Fair Value Update Signal Constructive Outlook
Analysts have made a small upward adjustment to the fair value estimate for Divi's Laboratories to around ₹6,875, reflecting slightly updated assumptions on the discount rate, revenue growth, profit margins and future P/E. What's in the News Board meeting scheduled on February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).ナラティブ更新 • Mar 08
DIVISLAB: Rich Future P/E Will Persist Despite Softer Outlook After Results
Analysts have trimmed their price target on Divi's Laboratories from ₹5,290 to ₹5,140, reflecting updated assumptions around a slightly lower revenue growth outlook, a marginally higher profit margin, a modestly reduced future P/E multiple, and an adjusted discount rate. What's in the News A board meeting is scheduled for February 11, 2026 to review and approve unaudited standalone and consolidated financial results for the quarter ended December 31, 2025 (Key Developments).ナラティブ更新 • Feb 22
DIVISLAB: Upcoming Results Review Will Shape Balanced Long Term Outlook
Narrative Update on Divi's Laboratories The analyst price target for Divi's Laboratories has been adjusted slightly higher from about ₹6,823 to roughly ₹6,870, with analysts pointing to small refinements in assumptions around discount rate, revenue growth, profit margin and future P/E as the drivers of this change. What's in the News A board meeting is scheduled for February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).ナラティブ更新 • Feb 07
DIVISLAB: Upcoming Results Review Will Support Bullish Long Term Outlook
Analysts have lifted their price target on Divi's Laboratories slightly to ₹6,823 from about ₹6,785, citing refreshed assumptions around discount rates, revenue growth, profit margin and future P/E that remain broadly in line with prior views. What's in the News A board meeting is scheduled for February 11, 2026, to review and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).ナラティブ更新 • Jan 24
DIVISLAB: Management Changes And Rich Future P/E Will Sustain Excessive Optimism
Analysts now cite slightly higher assumptions on growth, profitability and future P/E in their models for Divi's Laboratories, which feeds into an updated fair value estimate of ₹5,290, compared with the previous ₹5,035.89. What's in the News Board meeting scheduled for November 7, 2025, at 10:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).ナラティブ更新 • Jan 10
DIVISLAB: Upcoming Board Review And Management Changes Will Support Bullish Outlook
Analysts have raised their price target for Divi's Laboratories from ₹7,750 to about ₹8,554, citing updated assumptions related to revenue growth, profit margins and future P/E levels in their models. What's in the News Board meeting scheduled on Nov 07, 2025 at 10:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and half year ended Sep 30, 2025 (company filing).分析記事 • Dec 30
Earnings Not Telling The Story For Divi's Laboratories Limited (NSE:DIVISLAB)
Divi's Laboratories Limited's ( NSE:DIVISLAB ) price-to-earnings (or "P/E") ratio of 68.3x might make it look like a...ナラティブ更新 • Dec 25
DIVISLAB: Rising Profitability Expectations Will Mask Moderating Revenue And Justify Excessive Optimism
Analysts have raised their price target for Divi's Laboratories from ₹4,756 to ₹5,036, citing expectations of stronger profitability and a slightly richer future valuation multiple, despite moderating revenue growth assumptions. What's in the News Board meeting scheduled for November 7, 2025 at 10:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).ナラティブ更新 • Dec 11
DIVISLAB: Upcoming Board Meeting And Leadership Review Will Shape Fair Outlook
Analysts have nudged their price target for Divi's Laboratories slightly higher, reflecting marginal improvements in discount rate assumptions and long term growth expectations that together support a fair value estimate of ₹6,785.10 per share. What's in the News Board meeting scheduled for November 7, 2025, at 10:30 IST to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).分析記事 • Dec 09
Divi's Laboratories (NSE:DIVISLAB) Seems To Use Debt Quite Sensibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...ナラティブ更新 • Nov 27
DIVISLAB: Upcoming Board Decisions And Modest Earnings Improvements Will Shape Outlook
Analysts have raised their fair value estimate for Divi's Laboratories from ₹6,433 to ₹6,785, citing modest improvements in revenue growth and profit margin expectations. What's in the News A board meeting is scheduled for November 7, 2025, at 10:30 IST to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (Key Developments).分析記事 • Nov 15
Investors Shouldn't Be Too Comfortable With Divi's Laboratories' (NSE:DIVISLAB) Earnings
Despite posting some strong earnings, the market for Divi's Laboratories Limited's ( NSE:DIVISLAB ) stock hasn't moved...分析記事 • Nov 11
Divi's Laboratories Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Divi's Laboratories Limited ( NSE:DIVISLAB ) just released its latest interim results and things are looking bullish...ナラティブ更新 • Nov 08
DIVISLAB: Upcoming Board Decisions And Modest Earnings Improvements Will Shape Outlook
Analysts have modestly increased their price target for Divi's Laboratories from ₹6,363 to ₹6,433, citing slight improvements in projected revenue growth and profit margins as the underlying factors. What's in the News Upcoming Board Meeting scheduled for November 7, 2025, at 10:30 AM IST.分析記事 • Sep 06
Divi's Laboratories Limited's (NSE:DIVISLAB) Share Price Could Signal Some Risk
With a price-to-earnings (or "P/E") ratio of 69.2x Divi's Laboratories Limited ( NSE:DIVISLAB ) may be sending very...ナラティブ更新 • Sep 05
Custom Synthesis And Capacity Expansion Will Unlock Global Demand
With both the consensus price target and future P/E ratio for Divi's Laboratories remaining virtually unchanged, analysts signal stable valuation expectations, resulting in a steady fair value assessment at ₹6363. What's in the News Board meeting scheduled to consider and approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2025.分析記事 • Aug 10
Divi's Laboratories Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
NSEI:DIVISLAB 1 Year Share Price vs Fair Value Explore Divi's Laboratories's Fair Values from the Community and select...分析記事 • Aug 05
Most Shareholders Will Probably Agree With Divi's Laboratories Limited's (NSE:DIVISLAB) CEO Compensation
Key Insights Divi's Laboratories' Annual General Meeting to take place on 11th of August CEO Kiran Divi's total...
新しいナラティブ • Nov 10
Tactical Expansions And Innovation Could Offset Generic Pricing Pressures And Boost Profitability
Strategic investments in peptide synthesis and greenfield expansion enhance future revenue potential through capacity and product line growth.決済の安定と成長
配当データの取得
安定した配当: DIVISLABの1株当たり配当金は過去10年間安定しています。
増加する配当: DIVISLABの配当金は過去10年間にわたって増加しています。
配当利回り対市場
| Divi's Laboratories 配当利回り対市場 |
|---|
| セグメント | 配当利回り |
|---|---|
| 会社 (DIVISLAB) | 0.4% |
| 市場下位25% (IN) | 0.3% |
| 市場トップ25% (IN) | 1.4% |
| 業界平均 (Life Sciences) | 0.3% |
| アナリスト予想 (DIVISLAB) (最長3年) | 0.6% |
注目すべき配当: DIVISLABの配当金 ( 0.36% ) はIndian市場の配当金支払者の下位 25% ( 0.29% ) よりも高くなっています。
高配当: DIVISLABの配当金 ( 0.36% ) はIndian市場の配当金支払者の上位 25% ( 1.44% ) と比較すると低いです。
株主への利益配当
収益カバレッジ: DIVISLABの 配当性向 ( 31% ) はかなり低いため、配当金の支払いは利益によって十分にカバーされます。
株主配当金
キャッシュフローカバレッジ: DIVISLABは高い 現金配当性向 ( 365.3% ) のため、配当金の支払いはキャッシュフローで十分にカバーされていません。
高配当企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/08/04 11:54 |
| 終値 | 2026/08/04 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2026/03/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Divi's Laboratories Limited 29 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。52
| アナリスト | 機関 |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Gaurav Tinani | Ambit Capital |
| Pranav Chawla | Ambit Capital |